Alaunos Therapeutics, Inc. (TCRT)
TCRT moved a median of 0.00% 30 minutes after news, and -0.34% by the close. How TCRT actually reacts to news — the realized, point-in-time move the market made, measured across 134 labeled events over the last three years with zero look-ahead.
TCRT’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 34% | 114 |
| 30-min | 0.00% | 42% | 125 |
| 60-min | 0.00% | 47% | 134 |
| to close | -0.34% | 47% | 134 |
| Middle 50% of TCRT reactions | -1.63% to +2.50% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 134 |
Half of all Alaunos Therapeutics, Inc. news events land between -1.63% and +2.50% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when TCRT moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to TCRT's baseline. Nothing else.
Recent TCRT events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Alaunos Therapeutics Announces Acquisition of Velaris Therapeutics | Press release | GlobeNewswire | +1.08% | +64.67% | |
| Form 8-K Alaunos Therapeutics, For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | +17.14% | +73.14% | |
| Paragon Labs Expands Leadership Team with Former Apogee Executives; Velaris Therapeutics Acquired by Alaunos Therapeutics, Inc. | Press release | PR Newswire | +17.14% | +73.14% | |
| Form 8-K Alaunos Therapeutics, For: Oct 05 | SEC filing · Form 8-K | SEC EDGAR | +5.07% | +35.40% | |
| Form 8-K Alaunos Therapeutics, For: Sep 18 | SEC filing · Form 8-K | SEC EDGAR | -1.49% | -4.96% | |
| Alaunos Therapeutics, Inc. Announces Pricing of Registered Direct Offering priced at-the-market under Nasdaq rules | Press release | GlobeNewswire | -13.74% | -25.00% | |
| Form 8-K Alaunos Therapeutics, For: Sep 16 | SEC filing · Form 8-K | SEC EDGAR | -0.74% | +18.52% | |
| Form 10-Q Alaunos Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -2.44% | -6.83% | |
| Form S-8 Alaunos Therapeutics, | SEC filing · Form S-8 | SEC EDGAR | +0.00% | +0.94% | |
| Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study | Press release | GlobeNewswire | +3.41% | +7.73% | |
| Form 8-K Alaunos Therapeutics, For: Jun 29 | SEC filing · Form 8-K | SEC EDGAR | +3.41% | +7.73% | |
| Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies | Press release | GlobeNewswire | -1.63% | -0.41% | |
| Form 8-K Alaunos Therapeutics, For: May 26 | SEC filing · Form 8-K | SEC EDGAR | -4.35% | -3.16% | |
| Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models | Press release | GlobeNewswire | — | -0.80% | |
| Form 8-K Alaunos Therapeutics, For: May 18 | SEC filing · Form 8-K | SEC EDGAR | — | -0.80% | |
| Form 10-Q Alaunos Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | — | -0.80% | |
| Form 10-K/A Alaunos Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | -0.39% | +1.95% | |
| Form 8-K Alaunos Therapeutics, For: Apr 09 | SEC filing · Form 8-K | SEC EDGAR | +4.58% | -0.35% | |
| Form 10-K Alaunos Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | — | -0.34% | |
| Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders | Press release | GlobeNewswire | — | +6.07% | |
| Form 8-K Alaunos Therapeutics, For: Mar 02 | SEC filing · Form 8-K | SEC EDGAR | — | +6.07% | |
| Form 8-K Alaunos Therapeutics, For: Jan 08 | SEC filing · Form 8-K | SEC EDGAR | +5.76% | +7.27% | |
| Form 8-K Alaunos Therapeutics, For: Dec 17 | SEC filing · Form 8-K | SEC EDGAR | +1.68% | +2.92% | |
| Form 10-Q Alaunos Therapeutics, For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.09% | +7.69% | |
| Form S-3/A Alaunos Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.00% | +4.54% | |
| Form S-1 Alaunos Therapeutics, | SEC filing · Form S-1 | SEC EDGAR | +0.24% | -0.78% | |
| Form S-3/A Alaunos Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +2.82% | +6.05% | |
| Form S-3/A Alaunos Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | — | +4.07% | |
| Form S-3 Alaunos Therapeutics, | SEC filing · Form S-3 | SEC EDGAR | +0.52% | -4.54% | |
| Form 8-K Alaunos Therapeutics, For: Aug 19 | SEC filing · Form 8-K | SEC EDGAR | +0.52% | -4.54% | |
| Form 10-Q Alaunos Therapeutics, For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | -0.42% | -6.25% | |
| Form 8-K Alaunos Therapeutics, For: Jul 16 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | +3.68% | |
| Form 8-K Alaunos Therapeutics, For: Jul 15 | SEC filing · Form 8-K | SEC EDGAR | -0.58% | -6.63% | |
| Form 8-K Alaunos Therapeutics, For: Jul 03 | SEC filing · Form 8-K | SEC EDGAR | +3.07% | +2.25% | |
| Form 8-K Alaunos Therapeutics, For: Jul 01 | SEC filing · Form 8-K | SEC EDGAR | +0.20% | +2.25% | |
| Form 8-K Alaunos Therapeutics, For: Jun 20 | SEC filing · Form 8-K | SEC EDGAR | +0.30% | +13.32% | |
| Form 8-K Alaunos Therapeutics, For: Jun 24 | SEC filing · Form 8-K | SEC EDGAR | +0.30% | +13.32% | |
| Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering | Press release | GlobeNewswire | +10.14% | +12.14% | |
| Form 8-K Alaunos Therapeutics, For: Jun 09 | SEC filing · Form 8-K | SEC EDGAR | — | +3.69% | |
| Form 8-K Alaunos Therapeutics, For: May 19 | SEC filing · Form 8-K | SEC EDGAR | +0.21% | +1.54% | |
| Form ARS Alaunos Therapeutics, For: Dec 31 | SEC filing · Form ARS | SEC EDGAR | -0.76% | -3.05% | |
| Form DEF 14A Alaunos Therapeutics, For: Jul 03 | SEC filing · Form DEF | SEC EDGAR | -0.76% | -3.05% | |
| Form DEFA14A Alaunos Therapeutics, | SEC filing · Form DEFA14A | SEC EDGAR | -0.76% | -3.05% | |
| Form 10-Q Alaunos Therapeutics, For: Mar 31 | SEC filing · Form 10-Q | SEC EDGAR | -1.02% | -3.07% | |
| Form PRE 14A Alaunos Therapeutics, For: Jul 03 | SEC filing · Form PRE | SEC EDGAR | -1.76% | -3.39% | |
| Form 10-K/A Alaunos Therapeutics, For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +0.00% | -7.82% | |
| Form 8-K Alaunos Therapeutics, For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | +0.00% | -3.69% | |
| Form 8-K Alaunos Therapeutics, For: Apr 15 | SEC filing · Form 8-K | SEC EDGAR | -1.40% | -6.32% | |
| Form 8-K Alaunos Therapeutics, For: Apr 11 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | -10.36% | |
| Form 8-K Alaunos Therapeutics, For: Apr 07 | SEC filing · Form 8-K | SEC EDGAR | +0.79% | -10.36% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the TCRT section they belong to.
Where else TCRT is measured.
TCRT earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Alaunos Therapeutics, Inc.'s median reaction calculated?
Every labeled TCRT news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 134 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 42% of TCRT's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does TCRT's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.